INO Therapeutics Overview

  • Status
  • Acquired/​Merged

  • Employees
  • 463

Employees

  • Latest Deal Type
  • IPO
  • (Cancelled)

  • Financing Rounds
  • 2

INO Therapeutics General Information

Description

Manufacturer of late stage drugs for the treatment of heart and lung functions. The company's primary offering INOmax is used to carry oxygenated blood to the body tissues, and for the treatment of persistant pulmonary hypertension in the newborn.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Corporate Office
  • Six State Route 173
  • Clinton, NJ 08809
  • United States
+1 (908) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

INO Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore INO Therapeutics‘s full profile, request access.

Request a free trial

INO Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Daniel Tasse Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

INO Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

INO Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore INO Therapeutics‘s full profile, request access.

Request a free trial

INO Therapeutics FAQs

  • Who is the CEO of INO Therapeutics?

    Daniel Tasse is the CEO of INO Therapeutics.

  • Where is INO Therapeutics headquartered?

    INO Therapeutics is headquartered in Clinton, NJ.

  • What is the size of INO Therapeutics?

    INO Therapeutics has 463 total employees.

  • What industry is INO Therapeutics in?

    INO Therapeutics’s primary industry is Pharmaceuticals.

  • Is INO Therapeutics a private or public company?

    INO Therapeutics is a Private company.

  • What is the current valuation of INO Therapeutics?

    The current valuation of INO Therapeutics is 00000.

  • What is INO Therapeutics’s current revenue?

    The current revenue for INO Therapeutics is 000000.

  • Who are INO Therapeutics’s investors?

    Linde has invested in INO Therapeutics.

  • When was INO Therapeutics acquired?

    INO Therapeutics was acquired on 12-Nov-2010.

  • Who acquired INO Therapeutics?

    INO Therapeutics was acquired by Ikaria.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »